Pharmaceutical Research

, 36:145 | Cite as

Anti-GPC3 Antibody Tagged Cationic Switchable Lipid-Based Nanoparticles for the Co-Delivery of Anti-miRNA27a And Sorafenib in Liver Cancers

  • Zhengfeng WangEmail author
  • Kun Zhao
  • Yingxuan Zhang
  • Xinxin Duan
  • Yongfu Zhao
Research Paper



The immediate plasma metabolism and development of chemo-resistance (single agent) severely hampers the clinical effectiveness of Sorafenib (SRF) in liver cancer therapy. MicroRNA27a inhibition is a promising biological strategy for breast cancer therapy.


In this study, we aimed to prepare SRF and anti-miRNA27a-loaded anti-GPC3 antibody targeted lipid nanoparticles to enhance the therapeutic efficacy against liver cancers. In this study, we have employed a unique cationic switchable lipid (CSL) as a mean to encapsulate miRNA as well as to confer pH-responsiveness to the nanocarrier system.


The G-S27LN was nanosized and offered a pH-responsive release of SRF from the carrier system and we have demonstrated the specific affinity of G-S27LN towards the GPC3-overexpressed HepG2 cancer cells. Anti-microRNA27a significantly increased the protein expression of FOXO1 and PPAR-γ which are crucial components involved in proliferation and apoptosis of tumor cells. Combination of SRF and anti-miRNA27a (G-S27LN) resulted in significantly lower cell viability with a marked increase in the apoptosis cell proportion compared to that of free SRF indicating the synergistic anticancer effect. Animal studies in liver cancer xenograft model demonstrated significant suppression of tumor burden, reduced tumor cell and elevated TUNEL positive apoptosis with no toxicity concerns in animals treated with G-S27LN formulation.


The CSL-based G-S27LN efficiently co-delivered anti-microRNA27a and SRF and therefore represents a promising therapy to treat liver cancer. This study also brings forth a platform strategy for the effective treatment of number of other advanced cancers.

Key Words

anti-microRNA27a apoptosis lipid nanoparticles liver cancer sorafenib 



Cationic switchable lipid


Anti-GPC3 antibody-linked SRF/anti-miR27a-loaded lipid nanoparticles


Hepatocellular carcinoma


Micro RNA


SRF/anti-miR27a-loaded lipid nanoparticles





This study was supported by Youth Fund from the First Affiliated Hospital of Zhengzhou University.

Supplementary material

11095_2019_2669_MOESM1_ESM.docx (390 kb)
ESM 1 (DOCX 390 kb)


  1. 1.
    Chiang DY, Villanueva A. Progress towards molecular patient stratification of hepatocellular carcinoma: lost in translation? J Hepatol. 2017;67:893–5.CrossRefGoogle Scholar
  2. 2.
    Nakamura I, Iimuro Y, Hai S, Kondo Y, Hatano E, Fujimoto J. Impaired value of 99m Tc-GSA scintigraphy as an independent risk factor for posthepatectomy liver failure in patients with hepatocellular carcinoma. Eur Surg Res. 2018;9:12–22.CrossRefGoogle Scholar
  3. 3.
    Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014;63:844–55.CrossRefGoogle Scholar
  4. 4.
    Maluccio M, Covey A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin. 2012;62:394–9.CrossRefGoogle Scholar
  5. 5.
    Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, Allen C, et al. The burden of primary liver Cancer and underlying etiologies from 1990 to 2015 at the global, regional, and National Level: results from the global burden of disease study 2015. JAMA Oncol. 2017;3:1683–91.CrossRefGoogle Scholar
  6. 6.
    Abdel-Rahman O, Elsayed ZA. Combination trans arterial chemoembolization (TACE) plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review of the literature. Dig Dis Sci. 2013;58:3389–96.CrossRefGoogle Scholar
  7. 7.
    Miller AA, Murry DJ, Owzar K, Hollis DR, Kennedy EB, Abou-Alfa G, et al. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol. 2009;27:1800–5.CrossRefGoogle Scholar
  8. 8.
    Hl M, Kawada K, Ebi H, Kitagawa K, Kim YI, Araki K, et al. Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. Cancer Sci. 2008;99:1492–8.CrossRefGoogle Scholar
  9. 9.
    Strumberg D. Sorafenib for the treatment of renal cancer. Expert Opin Pharmacother. 2012;13:407–19.CrossRefGoogle Scholar
  10. 10.
    Oh YK, Park TG. siRNA delivery systems for cancer treatment. Adv DrugDeliv Rev. 2009;61:850–62.CrossRefGoogle Scholar
  11. 11.
    Llovet JM, Villanueva A, Lachenmayer A, Finn RS. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol. 2015;12:408–24.CrossRefGoogle Scholar
  12. 12.
    Huang S, He X. The role of microRNAs in liver cancer progression. Br J Cancer. 2011;104:235–40.CrossRefGoogle Scholar
  13. 13.
    Rossi JJ. New hope for a microRNA therapy for liver cancer. Cell. 2009;137:990–2.CrossRefGoogle Scholar
  14. 14.
    Wang Y, Chen F, Zhao M, Yang Z, Zhang S, Ye L, et al. MiR-107 suppresses proliferation of hepatoma cells through targeting HMGA2 mRNA 3′ UTR. Biochem Biophys Res Commun. 2016;480:455–60.CrossRefGoogle Scholar
  15. 15.
    Ge W, Yu DC, Li QG, Chen X, Zhang CY, Ding YT. Expression of serum miR-16, let-7f, and miR-21 in patients with hepatocellular carcinoma and their clinical significances. Clin Lab. 2014;60:427–34.CrossRefGoogle Scholar
  16. 16.
    Chen Z, Ma T, Huang C, Zhang L, Lv X, Xu T, et al. MiR-27a modulates the MDR1/P-glycoprotein expression by inhibiting FZD7/β-catenin pathway in hepatocellular carcinoma cells. Cell Signal. 2013;25:2693–701.CrossRefGoogle Scholar
  17. 17.
    Sun BZ, Li J, Shao D, Pan Y, Chen Y, Li S, et al. Adipose tissue-secreted miR-27a promotes liver cancer by targeting FOXO1 in obese individuals. Onco Targets Ther. 2015;8:735–44.CrossRefGoogle Scholar
  18. 18.
    Li S, Li J, Fei BY, Shao D, Pan Y, Mo ZH, et al. MiR-27a promotes hepatocellular carcinoma cell proliferation through suppression of its target gene peroxisome proliferator-activated receptor γ. Chin Med J. 2015;128:941–7.CrossRefGoogle Scholar
  19. 19.
    Kasinski A, Slack FJ. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer. 2011;11:849–64.CrossRefGoogle Scholar
  20. 20.
    Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol. 2011;13:423–33.CrossRefGoogle Scholar
  21. 21.
    Poudel BK, Gupta B, Ramasamy T, Thapa RK, Youn YS, Choi HG, et al. Development of polymeric irinotecan nanoparticles using a novel lactone preservation strategy. Int J Pharm. 2016;512:75–86.CrossRefGoogle Scholar
  22. 22.
    Ball RL, Hajj KA, Vizelman J, Bajaj P, Whitehead KA. Lipid nanoparticle formulations for enhanced co-delivery of siRNA and Mrna. Nano Lett. 2018;18:3814–22.CrossRefGoogle Scholar
  23. 23.
    Viricel W, Mbarek A, Leblond J. Switchable lipids: conformational change for fast pH-triggered cytoplasmic delivery. Angew Chem Int Ed Eng. 2015;54:12743–7.CrossRefGoogle Scholar
  24. 24.
    Viricel W, Poirier S, Mbarek A, Derbali RM, Mayer G, Leblond J. Cationic switchable lipids: pH-triggered molecular switch for siRNA delivery. Nanoscale. 2016;9:31–6.CrossRefGoogle Scholar
  25. 25.
    Viricel W, Poirier S, Mbarek A, Derbali RM, Mayer G. J Leblond Cationic switchable lipids: pH-triggered molecular switch for siRNA delivery. Nanoscale. 2017;9:31.CrossRefGoogle Scholar
  26. 26.
    Ramasamy T, Ruttala HB, Gupta B, Poudel BK, Choi HG, Yong CS, et al. Smart chemistry-based nanosized drug delivery systems for systemic applications: a comprehensive review. J Control Release. 2017;258:226–53.CrossRefGoogle Scholar
  27. 27.
    Choi JY, Gupta B, Ramasamy T, Jeong JH, Jin SG, Choi HG, et al. PEGylated polyaminoacid-capped mesoporous silica nanoparticles for mitochondria-targeted delivery of celastrol in solid tumors. Colloids Surf B: Biointerfaces. 2018;165:56–66.CrossRefGoogle Scholar
  28. 28.
    Mehta SB, Carpenter JF, Randolph TW. Colloidal instability fosters agglomeration of subvisible particles created by rupture of gels of a monoclonal antibody formed at silicone oil-water interfaces. J Pharm Sci. 2016;105(8):2338–48.CrossRefGoogle Scholar
  29. 29.
    Kim SY, Kim AY, Lee HW, Son YH, Lee GY, Lee JW, et al. miR-27a is a negative regulator of adipocyte differentiation via suppressing PPARγ expression. Biochem Biophys Res Commun. 2010;392:323–8.CrossRefGoogle Scholar
  30. 30.
    Yu Y, Du HW, Wei SN, Feng LJ, Li JN, Yao F, et al. Adipocyte-derived Exosomal MiR-27a induces insulin resistance in skeletal muscle through repression of PPARγ. Theranostics. 2018;8:2171–88.CrossRefGoogle Scholar
  31. 31.
    Zhang H, Li M, Han Y, Hong L, Gong T, Sun L, et al. Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma. Dig Dis Sci. 2010;55:2545–51.CrossRefGoogle Scholar
  32. 32.
    Zhao X, Yang L, Hu J. Down-regulation of miR-27a might inhibit proliferation and drug resistance of gastric cancer cells. J Exp Clin Cancer Res. 2011;30:55.CrossRefGoogle Scholar
  33. 33.
    Kim MS, Saunders AM, Hamaoka BY, Beachy PA, Leahy DJ. Structure of the protein core of the glypican dally-like and localization of a region important for hedgehog signaling. Proc Natl Acad Sci U S A. 2011;108:13112–7.CrossRefGoogle Scholar
  34. 34.
    Avanesov A, Honeyager SM, Malicki J, Blair SS. The role of glypicans in Wnt inhibitory factor-1 activity and the structural basis of Wif1's effects on Wnt and hedgehog signaling. PLoS Genet. 2012;8:e100250.CrossRefGoogle Scholar
  35. 35.
    Zhu H, Wu H, Liu X, Evans BR, Medina DJ, Liu CG, et al. Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol. 2008;76:582–8.CrossRefGoogle Scholar
  36. 36.
    Guttilla IK, White BA. Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells. J Biol Chem. 2009;284:23204–16.CrossRefGoogle Scholar
  37. 37.
    Gao Z, Zhang L, Sun Y. Nanotechnology applied to overcome tumor drug resistance. J Control Release. 2012;162:45–55.CrossRefGoogle Scholar
  38. 38.
    Liu G, Shen H, Mao J, Zhang L, Jiang Z, Sun T. Transferrin modified graphene oxide for gliomatargeted drug delivery: in vitro and in vivo evaluations. ACS Appl Mater Interfaces. 2013;5:6909–14.CrossRefGoogle Scholar
  39. 39.
    Ramasamy T, Ruttala HB, Chitrapriya N, Poudal BK, Choi JY, Kim ST, et al. Engineering of cell microenvironment-responsive polypeptide nanovehicle co-encapsulating a synergistic combination of small molecules for effective chemotherapy in solid tumors. Acta Biomater. 2017 Jan 15;48:131–43.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Hepatobiliary SurgeryThe First Affiliated Hospital of Zhengzhou UniversityZhengzhouChina

Personalised recommendations